SIRT1 and metabolic dysfunction-associated steatotic liver disease: Our laboratory has reported that CA exerts an antiapoptotic effect during liver ischemia/reperfusion injury by activating the SIRT1/p66shc pathway.17 SIRT1, an NAD-dependent deacetylase, is the best-characterized direct target of miR-34a.28 In addition, the apoptotic pathway that is regulated by the miR-34a/SIRT1 axis is involved in numerous diseases.28, 29, 30 Therefore, we investigated whether the protective effect of CA against NAFLD involves miR-34a regulation and promotion of the SIRT1/p66shc pathway.